FTH Faeth Therapeutics, Inc.

NASDAQ
$28.35

Faeth Therapeutics, Inc. (FTH) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Bullish Insiders bought more than they sold over this window — uncommon at any size.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 0 sellers in the last 90 days
Insiders buying
2
23 transactions
Insiders selling
2
4 transactions
Purchases
$1.2M
49,494 shares
Sales
$1.0M
50,000 shares
Net activity
$187.7K
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $1.0M 4 transactions · 50,000 shares

Largest single sale: $490.5K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: July 1, 2026 , by STEPHENSON BRIAN C .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
STEPHENSON BRIAN C 2 fills Chief Financial Officer Buy 5,000 $23.50 $117.5K 46,688
STEPHENSON BRIAN C 3 fills Chief Financial Officer Buy 7,803 $24.25 $189.2K 41,688
STEPHENSON BRIAN C Chief Financial Officer Buy 831 $23.34 $19.4K 33,885
STEPHENSON BRIAN C 4 fills Chief Financial Officer Buy 6,250 $24.95 $155.9K 33,054
STEPHENSON BRIAN C 4 fills Chief Financial Officer Buy 9,391 $26.13 $245.4K 26,804
STEPHENSON BRIAN C 3 fills Chief Financial Officer Buy 9,230 $24.36 $224.8K 17,413
STEPHENSON BRIAN C 5 fills Chief Financial Officer Buy 8,183 $22.13 $181.1K 8,183
Parikh Anand Kiran President and CEO Buy 2,806 $19.76 $55.4K 764,234
Cambrian BioPharma Inc 2 fills 10% Owner Sell 25,000 $20.02 $500.5K 130,618 −16.1% of holding
Peyer James 2 fills 10% Owner Sell 25,000 $20.02 $500.5K 130,618 −16.1% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.